TrovaGene (NASDAQ:TROV) reported that for Q4, it narrowed its loss year over year, beating Street estimates, while revenue fell versus the prior year period and fell short of analysts’ expectations. The development-stage molecular diagnostic company reported a Q4 net loss of $1 million, or $0.05 per share, compared with the prior-year period’s net loss of $6.3 million, or $0.43 per share. Revenue was $47,000 down from $163,000 in the same quarter last year. The average estimate from two analysts on Capital IQ was for a loss per share of $0.19 on revenues of million.
Trovagene (NASDAQ:TROV) shares closed at $6.20, up 6.53% for the day. The company has a 52 week range of 5.95-6.51 and an average volume of 59,771. The company is 21% owned by institutions and has an overall market cap of 127.53 million. TROV has a one year target estimate of $10.00 and holds a mean recommendation of 2.0, according to First Call.
AstraZeneca plc (ADR) (NYSE:AZN) shares were up about 1% in late Monday trading after the drug-maker earlier today reported progress in a clinical trial of its ticagrelor drug candidate in patients with high-risk cardiovascular disease, completing enrollment in the Phase III testing four months ahead of schedule. Overall, more than 13,500 patients worldwide with peripheral artery disease have now been enrolled in the trial, including around 2700 in the United States from over 300 trial sites across the country. The trial was designed to evaluate the effects of ticagrelor, which will be marketed commercially as Brilinta, compared to a previously approved blood-thinner, Plavix (clopidogrel), on cardiovascular events.
AstraZeneca plc (ADR) (NYSE:AZN) today also said it was expanding its late-stage testing of ticagrelor to two more studies intended to compare the efficacy of the drug with aspirin in reducing major vascular events in patients with acute ischemic stroke or transient ischemic attacks. AstraZeneca (NYSE:AZN) shares were up 1% at $65.95 each in recent trade, earlier climbing as high as $66.21 during today’s session. The stock has a 52-week range of $46.01 to $68.76 a share.
Shares of Life Partners Holdings Inc. (NASDAQ:LPHI) jumped more than 30% last week after a federal jury in Texas ruled the Securities and Exchange Commission failed to prove any of its fraud claims against the life-settlements company, CEO Brian Pardo and its general counsel, Scott Peden. The U.S. District Court jury in Austin, Texas, also sided with the company and its revenue recognition policies, deciding there was no evidence supporting prosecution charges of fraud. But the Court let stand misdemeanor charges over its bookkeeping and reporting procedures along with mistakes in the chief executive’s certification of the company’s financial statements.
Life Partners Holdings Inc. (NASDAQ:LPHI), which buys and pays on a portion of life insurance policies in the secondary market, saw shares jump 1.02% at $2.96 apiece in recent trade, earlier advancing to an intra-day high of $3.00. The stock has a 52-week range of $1.52 to $4.26 a share.
Alliance HealthCare Services Inc. (NASDAQ:AIQ) was unchanged in late Wednesday trading after the outsourced radiology-services company narrowed its net loss during the three months ended Dec. 31 compared to same quarter the prior year. The company also is projecting revenue growth this year of up to 3% over FY13 levels. Alliance HealthCare (NASDAQ:AIQ) posted a Q4 GAAP net loss of $4.0 million, or $0.38 per share, improving on a $0.48 per share million net loss in the year-ago period.
Excluding a $0.64 per share charge during the quarter linked to retiring debt as well as restructuring and transaction costs and other non-recurring charges, the company earned $0.26 per share, improving on a $0.22 per share net loss last year. Revenue declined 3.5% year over year to $110.7 million. No analyst estimates were available for comparison. Alliance HealthCare Services Inc. (NASDAQ:AIQ) also is expecting revenue during the 12 months ending in December in a range of $437 million to $462 million, representing a decline of 2.6% to a rise of $2.9% over the company’s $448.8 million in FY13 revenue.